A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
Key facts
- Who runs it
- UCB Biopharma SRL
- Where
- United Kingdom7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 63 people enrolled
- Started
- 21 Dec 2022
- Ended
- 9 Jul 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- rozanolixizumab
- Placebo
- Record updated
- 1 July 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Study participant must be ≥18 years and ≤70 years of age at the time of signing the informed consent form (ICF)
- Study participant with a diagnosis of fibromyalgia as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary; Diagnostic Criteria) plus the following characteristics during the Screening Period:
- Brief Pain Inventory-short form (BPI-SF) interference score ≥6
- Study participant has been diagnosed with fibromyalgia syndrome (FMS) for at least 6 months
- Study participant has been having FMS symptomatology for at least 2 years before enrollment - Capable of giving signed informed consent as described in the Protocol which includes compliance with the requirements and restrictions listed in the ICF and in the Study Protocol
Who cannot take part
- Study participant has any systemic autoimmune inflammatory disease
- Study participant has any medical or psychiatric or separate chronic pain condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study or the ability to assess FMS-related pain
- Study participant has severe renal impairment, defined as estimated glomerular filtration rate <30 mL/min/1.73 m\^2, (calculated using Modification of Diet in Renal Disease [MDRD] study equation), at Screening visit
- Study participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator
- Study participant has a current or medical history of primary immunodeficiency
- Study participant has been diagnosed with fibromyalgia syndrome (FMS) for >15 years
- Study participant has chronic inflammatory demyelinating polyneuropathy
- Study participant is pregnant or lactating
- Study participant; Has suicide attempt in the past 2 years (including an active attempt, interrupted attempt, or aborted attempt),; OR had suicidal ideation with at least some intent to act in the past 6 months as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening or Baseline (Visit 3); OR is otherwise judged clinically to be at a serious suicidal risk based on the investigator's judgment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).
The 3 groups in the trial
- Treatment sequence 1Treatment being tested
Study participants on Treatment sequence 1 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
Treatment: rozanolixizumab and Placebo
- Treatment sequence 2Treatment being tested
Study participants on Treatment sequence 2 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
Treatment: rozanolixizumab and Placebo
- Treatment sequence 3Placebo, for comparison
Study participants on Treatment sequence 3 will receive Placebo during the dosing period at pre-specified timepoints.
Treatment: Placebo
Results explained
A paper that names this trial, explained in plain words.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2A, Proof-Of-Concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
- Publications
- Record updated
- 1 July 2025